Caplin Point Laboratories Limited

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:00:37 2024-05-18 am EDT			5-day change	1st Jan Change
1,315 ^INR	-1.77%		+0.70%	-3.05%

May. 16	Caplin Point Laboratories to Seek Acquisitions	CI
May. 16	Transcript : Caplin Point Laboratories Limited, Q4 2024 Earnings Call, May 16, 2024

Caplin Point Laboratories Limited Approves Interim Dividend for the Financial Year 2022-23

May 27, 2023 at 03:14 am EDT

Caplin Point Laboratories Limited approved an interim dividend of INR 2/- (100 %) per equity share of INR 2/- each for the Financial Year 2022-23. Fixed June 9, 2023 as Record Date for determining the eligibility of the Shareholders for the purpose of Interim Dividend.

Latest news about Caplin Point Laboratories Limited

Caplin Point Laboratories to Seek Acquisitions	May. 16	CI
Transcript : Caplin Point Laboratories Limited, Q4 2024 Earnings Call, May 16, 2024	May. 16
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024	May. 16	CI
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 16	CI
Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India	May. 06	MT
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution	Apr. 16	MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication	Mar. 28	MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution	Mar. 28	CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India	Mar. 27	MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations	Mar. 27	CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 09
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 09	CI
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India	Jan. 08	MT
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug	Jan. 08	MT
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D	Dec. 14	CI
Transcript : Caplin Point Laboratories Limited, H1 2024 Earnings Call, Nov 09, 2023	Nov. 09
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023	23-09-22	CI
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA	23-09-04	MT
Transcript : Caplin Point Laboratories Limited, Q1 2024 Earnings Call, Aug 08, 2023	23-08-08
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-07	CI
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023	23-08-07	CI
Caplin Point Laboratories to Incorporate Step-Down Subsidiary in US	23-08-03	MT
Caplin Point Unit Gets US FDA Nod for Muscle Relaxant	23-06-12	MT
Caplin Steriles Limited Gets United States Food and Drug Administration Approval for Cisatracurium Besylate Injection USP	23-06-12	CI

Chart Caplin Point Laboratories Limited

Duration

Period

More charts

Company Profile

Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Companyâs subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Caplin Point Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,338 INR

Average target price

1,579 INR

Spread / Average Target

+17.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CAPLIN POINT LABORATORIES LIMITED	-3.05%	1.22B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.11B
OTSUKA HOLDINGS CO., LTD.	+23.03%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.56B
ZYDUS LIFESCIENCES LIMITED	+60.18%	12.7B
ONO PHARMACEUTICAL CO., LTD.	-10.02%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals